Vaccines for COVID-19: Where do we stand in 2021?

被引:61
|
作者
Sharma, Ketaki [1 ,2 ]
Koirala, Archana [1 ,2 ,3 ]
Nicolopoulos, Katrina [1 ]
Chiu, Clayton [1 ,2 ]
Wood, Nicholas [1 ,2 ]
Britton, Philip N. [2 ,4 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Nepean Hosp, Dept Infect Dis, Penrith, NSW, Australia
[4] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Westmead, NSW, Australia
关键词
COVID-19; SARS-CoV-2; Vaccines; vaccines; NCOV-19; AZD1222; VACCINE; EFFICACY; BNT162B2; SCOTLAND; RISK;
D O I
10.1016/j.prrv.2021.07.001
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARSCoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity. Crown Copyright (c) 2021 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:22 / 31
页数:10
相关论文
共 50 条
  • [21] COVID-19 pandemic and cardiovascular disease: where do we stand?
    Chatzis, Dimitrios G.
    Magounaki, Kalliopi T.
    Pantazopoulos, Ioannis N.
    Johnson, Elizabeth O.
    Tsioufis, Konstantinos P.
    MINERVA CARDIOANGIOLOGICA, 2020, 68 (04): : 347 - 358
  • [22] COVID-19 after 18 months: Where do we stand?
    Chassagnon, Guillaume
    Regarda, Lucile
    Soyera, Philippe
    Revel, Marie-Pierre
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2021, 102 (09) : 491 - 492
  • [23] Where do we stand with antithrombotic prophylaxis in patients with COVID-19?
    Ciavarella, Alessandro
    Peyvandi, Flora
    Martinelli, Ida
    THROMBOSIS RESEARCH, 2020, 191 : 29 - 29
  • [24] COVID-19 and ABO blood types: Where do we stand?
    Le Pendu, Jacques
    Breiman, Adrien
    Deleers, Marie
    El Kenz, Hanane
    Ruvoen, Nathalie
    M S-MEDECINE SCIENCES, 2021, 37 (6-7): : 565 - 568
  • [25] Directly Acting Antivirals for COVID-19: Where Do We Stand?
    Teoh, Siew L.
    Lim, Yi H.
    Lai, Nai M.
    Lee, Shaun W. H.
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [26] Covid-19: Where are we on immunity and vaccines?
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 370 : m3096
  • [27] Covid-19: Where are we on vaccines and variants?
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 372 : n597
  • [28] Abstract for Symposium COVID-19 and suicides in India: Where do we stand?
    Vijayakumar, Lakshmi
    Sarkhel, Sujit
    Mehta, Varun S.
    INDIAN JOURNAL OF PSYCHIATRY, 2022, 64
  • [29] Genetic Predisposition and Inflammatory Inhibitors in COVID-19: Where Do We Stand?
    Sagris, Marios
    Theofilis, Panagiotis
    Antonopoulos, Alexios S.
    Oikonomou, Evangelos
    Tsioufis, Kostas
    Tousoulis, Dimitris
    BIOMEDICINES, 2022, 10 (02)
  • [30] Abstract for Symposium COVID-19 and suicides in India: Where do we stand?
    Vijayakumar, Lakshmi
    Sarkhel, Sujit
    Mehta, Varun S.
    INDIAN JOURNAL OF PSYCHIATRY, 2022, 64 (SUPPL 3) : S648 - S649